Brief: TG Therapeutics To Present Data From The Ultimate I & II Phase 3 Trials Of BRIUMVI(ublituximab-xiiy)
24/02/2023 15:40
Feb 24 (Reuters) - TG Therapeutics Inc TGTX.O :
* TG THERAPEUTICS ANNOUNCES PRESENTATION OF DATA FROM THE
ULTIMATE
I & II PHASE 3 TRIALS OF BRIUMVI™ (UBLITUXIMAB-XIIY) IN MULTIPLE
SCLEROSIS AT THE AMERICAS COMMITTEE FOR TREATMENT AND RESEARCH
IN MULTIPLE SCLEROSIS ANNUAL FORUM
Source text for Eikon: ID:nGNX1hfRb9
Further company coverage: TGTX.O
Recent news on TG Therapeutics
See all newsTG Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tg Therapeutics Reports Second Quarter 2026 Financial Results And Raises Briumvi® Revenue Guidance
TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj